Open-label, Randomized, Crossover Study to Prove Bioequivalence Between Opxion (Levonorgestrel 0.75 mg From Bayer de Mexico) and Postday (Levonorgestrel 0.75 mg From Investigacion Farmaceutica), in Healthy Volunteers.
Latest Information Update: 21 Jun 2012
At a glance
- Drugs Levonorgestrel (Primary)
- Indications Pregnancy
- Focus Pharmacokinetics
- Acronyms LEVEQ-2
- Sponsors Bayer
Most Recent Events
- 05 Apr 2010 New trial record